Literature DB >> 30226611

Allergen‑removed Rhus verniciflua Stokes suppresses invasion and migration of pancreatic cancer cells through downregulation of the JAK/STAT and Src/FAK signaling pathways.

Youra Kang1, Seong Woo Yoon2, Byoungduck Park3.   

Abstract

Pancreatic cancer is a leading cause of mortality and morbidity worldwide. Due to drug resistance, and the high toxicity and adverse side effects of existing chemotherapeutic drugs, the current treatment of highly aggressive pancreatic cancer is considered inadequate. Allergen‑removed Rhus verniciflua Stokes (aRVS) has a strong antiproliferative effect in various cancer cells, and due to its low toxicity, it has emerged as an attractive candidate for cancer treatment. However, the potential use of aRVS as a treatment for pancreatic cancer is relatively unexplored. The present study examined the effects of aRVS on the invasion and migration of pancreatic cancer cells, and identified the molecular mechanisms underlying its anticancer effects. aRVS inhibited the Janus kinase/signal transducer and activator of transcription pathway in pancreatic cancer cells, and decreased the protein expression of mucin 4. In addition, it inhibited the activation of focal adhesion kinase and Src signaling, and decreased the expression of matrix metalloproteinase 9, which may reduce the migration and invasion of pancreatic cancer cells. In conclusion, the present study suggested that aRVS may be a potential treatment for aggressive pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30226611     DOI: 10.3892/or.2018.6699

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Exploration of the System-Level Mechanisms of the Herbal Drug FDY003 for Pancreatic Cancer Treatment: A Network Pharmacological Investigation.

Authors:  Ho-Sung Lee; In-Hee Lee; Kyungrae Kang; Sang-In Park; Minho Jung; Seung Gu Yang; Tae-Wook Kwon; Dae-Yeon Lee
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-10       Impact factor: 2.650

2.  Carcinoma-associated fibroblasts release microRNA-331-3p containing extracellular vesicles to exacerbate the development of pancreatic cancer via the SCARA5-FAK axis.

Authors:  Yadong Han; Xu Qian; Teng Xu; Yang Shi
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.875

3.  Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.

Authors:  Xiao-Guang Liu; Hao Xu; Ming Chen; Xiao-Yu Tan; Xiao-Feng Chen; Yong-Guang Yang; Man-Zhou Lin; Guo-Hua Liu; Xiao-Lu Liang; Yi-Bin Qian; Guo-Jia Yuan; Min-Qiang Chen; Wen-Tao Li; Hui-Lai Miao; Ming-Yi Li; Xi-Wen Liao; Wei Dai; Nian-Ping Chen
Journal:  Cancer Med       Date:  2020-01-28       Impact factor: 4.452

4.  Genotoxicity of Water Extract from Bark-Removed Rhus verniciflua Stokes.

Authors:  Sung-Bae Lee; Jin-Seok Lee; Jing-Hua Wang; Min-Young Kim; Yung-Hyun Choi; Hwa-Dong Lee; Chang-Gue Son
Journal:  Molecules       Date:  2021-02-08       Impact factor: 4.411

5.  UXT antisense RNA 1 sever as a novel prognostic long non-coding RNA in early stage pancreatic ductal adenocarcinoma patients after receiving pancreaticoduodenectomy.

Authors:  Xiwen Liao; Rui Huang; Xiangkun Wang; Ketuan Huang; Chengkun Yang; Xin Zhou; Chuangye Han; Hao Su; Xinping Ye; Kang Liu; Guangzhi Zhu; Tao Peng
Journal:  J Cancer       Date:  2021-02-21       Impact factor: 4.207

6.  Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds.

Authors:  Wei Li; Tae In Kim; Ji Hye Kim; Hwan-Suck Chung
Journal:  Molecules       Date:  2019-11-09       Impact factor: 4.411

7.  Overexpression of Eukaryotic translation initiation factor 3D induces stem cell-like properties and metastasis in cervix cancer by activating FAK through inhibiting degradation of GRP78.

Authors:  Yan Zhong; Jian Lan
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.